Reviewed 3 November 2026. This article focuses on regenerative medical products in Japan; the figures below are dated snapshots, not a live product list.
“PMDA approved” usually means a product has received Japanese marketing approval following scientific review by the Pharmaceuticals and Medical Devices Agency (PMDA). PMDA reviews the evidence; Japan’s Ministry of Health, Labour and Welfare (MHLW) grants the approval. For regenerative medical products, approval applies to the named product and its specified uses and conditions—not to stem cell therapy as a whole. PMDA reported 26 approved regenerative medical products as of 20 May 2026, excluding withdrawn or expired products. 000280868.pdf

A clinic’s treatment-plan filing is different. MHLW reported 6,743 treatment plans as of 30 June 2026 under a separate regulatory route; that count does not mean 6,743 treatments had received product approval or demonstrated efficacy. 001590173.pdf
If a clinic says a treatment is “PMDA approved,” ask: which product, for which indication, and is that approval still valid?
Who Actually Approves the Product?
A company seeking to market a regenerative medical product submits information on quality, safety, and efficacy for regulatory review under the Pharmaceuticals and Medical Devices Act (PMD Act). Its application specifies the product’s indications, manufacturing method, quality specifications, and dosage and administration or usage. 000277611.pdf
PMDA conducts the scientific review. The formal product-approval decision comes from the MHLW Minister following the required deliberations. PMDA publishes product-specific review reports that help readers check what was reviewed and for which use. An old report should be read alongside later status notices and the current package insert—not treated as proof that an approval remains valid today. 0003
For cell treatments provided under the Act on the Safety of Regenerative Medicine, the applicable process includes committee review and submission of a provision plan. This is not the PMD Act product-approval route. A plan filing alone does not establish that the treatment works; some uses of approved products are also excluded from the plan-filing requirements. Plan The distinction between these routes is explained in the overview of Japan’s regenerative medicine registration and compliance.
Why Are Approvals and Filings Different?
PMDA’s May 2026 presentation lists 28 historical product approvals, leaving 26 after excluding one withdrawal and one expiry. The category includes gene therapies and cell- and tissue-based products; it is not a count of stem cell treatments alone. 000280868.pdf
MHLW’s June 2026 report counts 6,743 treatment plans: 8 Class I, 2,463 Class II, and 4,272 Class III. It separately counts 85 research plans. These are plan counts, not numbers of unique clinics, patients, approved products, or successful outcomes. 001590173.pdf
The risk classes determine regulatory requirements, not a treatment’s effectiveness. Because the two totals use different units, legal routes, and dates, dividing approvals by filings would not produce an approval rate or a patient’s chance of benefit.
What Does an Approval Cover?
Approval is tied to a defined product, including its manufacturing process and quality specifications. Its approved indication states the condition it may be marketed to treat; the dosage and administration specify how it is used. Another clinic’s preparation does not inherit that approval just because it uses cells with a similar name. Compare the exact product, indication, eligible population, dose, and administration route with the approved information. 000277611.pdf
A United States example shows why those details matter, without establishing approval in Japan. On 18 December 2024, the FDA approved Ryoncil (remestemcel-L-rknd), a donor bone-marrow-derived mesenchymal stromal cell product administered intravenously, for steroid-refractory acute graft-versus-host disease in children aged 2 months and older following donor transplantation. In its multicenter single-arm study of 54 children, 16 had a complete response (30%) and 22 had a partial response (41%) at day 28. There was no concurrent comparison group, and day-28 response is not a measure of long-term cure. Common adverse reactions included infections, fever, hemorrhage, edema, abdominal pain, and hypertension. These results do not establish benefits for arthritis, fatigue, or anti-aging. Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host
What Does Conditional Approval Mean?
Japan’s conditional and time-limited approval pathway allows qualifying regenerative medical products to be marketed when efficacy is presumed and safety has been established to the standard required for that pathway. It is not a guarantee of safety or confirmed efficacy. The company must collect further clinical data and apply again within the specified period. The statutory period is up to seven years, with an extension of up to three years only under specified conditions. 000280868.pdf Conditional approval does not automatically convert to full approval. 000277616.pdf
- HeartSheet, an autologous skeletal myoblast-derived cell sheet for severe heart failure, received conditional and time-limited approval in September 2015. The later application did not obtain full approval. 0003 The July 2024 deliberation report states that post-approval investigations had not demonstrated efficacy for the proposed indication. The Committee on Regenerative Medicine Products and Biotechnology reached its conclusion on 19 July; the Pharmaceutical Affairs Council supported the non-approval conclusion on 24 July. 000272880.pdf The approval was withdrawn on 25 July 2024. 000280868.pdf
- Collategene received conditional and time-limited approval in March 2019. That approval expired in June 2024 rather than converting to full approval. 000277616.pdf
For any conditionally approved product, check the individual deadline, outstanding evidence requirements, and latest regulatory outcome. Do not assume every product has the same approval period.
What Approval Does Not Mean
| Claim you may hear | What to check | What it does not establish |
|---|---|---|
| “PMDA approved” | The exact product, indication, eligible patients, administration, current status, and conditions | Approval of another preparation, another disease, or a clinic’s entire treatment menu |
| “Filed with the government” | The provision plan, risk class, committee review, and consent documents | Product approval or proof of efficacy |
| “Registered trial” | The study identity, eligibility, recruitment status, and any published results | Successful results or marketing approval |
| “Covered by insurance” or “self-pay” | The billing rules for the particular care proposed | That payment status alone proves approval or suitability |
| “Approved abroad” | The country, named product, approved indication, and patient group | Japanese marketing approval |
An FDA approval is not a Japanese approval; check the Japanese record if treatment will take place in Japan. 0003 Resolve the regulatory-route and documentation questions before arranging treatment-related travel, using the preparation steps in the medical travel guide for stem cell treatment in Japan.
How Can You Check an Approval Claim?
The HeartSheet documents provide a practical example: its original approval date and its later non-approval outcome appear in the regulatory record. The July 2024 report explains why the later application was not approved. Checking only the original date would miss the outcome that matters to a present-day decision. 000272880.pdf This is a document-checking example, not a patient case or firsthand clinical experience.
- Get the exact product name. “Stem cell infusion” is not enough. Ask for the brand and product identity shown in the approval documents.
- Match the proposed use. Compare the disease, disease stage where specified, eligible patients, dose, and route. A different disease or route is not covered by the approval you were shown. The same matching questions help when choosing a stem cell hospital in Japan.
- Check status, not just the original approval date. Request the approval number, current package insert, and any conditions or expiry date. Use PMDA’s review-report listing to identify the product and follow through to later regulatory information. 0003
- Identify the route for your care. Ask whether the offer involves an approved product within its approved use, a provision plan under the Safety Act, or research. Keep copies of the relevant documents.
- Pause if the paperwork is unclear. Do not let an upfront-payment deadline replace an explanation. Ask your own disease specialist to review the proposed care before you pay or travel.
Have questions about the documents for proposed care in Japan? Contact the patient support team about the paperwork and appointment process. Regulatory status should be checked against official records; treatment suitability requires a clinician’s assessment.
Does Approval Mean It Will Work for You?
No. Approval is a regulatory decision about a defined product and use, not a promise of benefit for every patient. Adverse reactions and follow-up needs remain relevant. Conditional approval also carries unresolved efficacy questions that the required post-marketing evidence is intended to address. 000280868.pdf
Animal results, testimonials, and trial registration cannot replace human evidence for your diagnosis, patient group, cell product, dose, route, and outcome. Ask what benefits were measured, over what follow-up period, against what comparison, and with which harms. An early response percentage should not be presented as a long-term cure rate.
The Answer in Brief
“PMDA approved” refers to Japanese product approval following PMDA review—not blanket approval of a clinic or of stem cells. The 26 approved products reported in May 2026 and 6,743 treatment plans reported in June 2026 describe different regulatory routes. Before relying on an approval claim, confirm the exact product, approved use, current status, and conditions.




